1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Drugs In Development, 2022, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 11 and 2 respectively.
Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Short Bowel Syndrome - Overview
- Short Bowel Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Short Bowel Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Short Bowel Syndrome - Companies Involved in Therapeutics Development
- 9 Meters Biopharma Inc
- Amogen Pharma Pvt Ltd
- Applied Molecular Transport Inc
- enGene Inc
- Entera Bio Ltd
- Hanmi Pharmaceuticals Co Ltd
- Huons Global Co Ltd
- Micelle BioPharma Inc
- Napo Pharmaceuticals Inc
- OPKO Health Inc
- PhaseBio Pharmaceuticals Inc
- QuiaPEG Pharmaceuticals AB
- Surrozen Inc
- Takeda Pharmaceutical Co Ltd
- Tasly Pharmaceutical Group Co Ltd
- VectivBio Holding AG
- Worphmed Srl
- Zealand Pharma AS
- Short Bowel Syndrome - Drug Profiles
- apraglutide - Drug Profile
- Product Description
- Mechanism Of Action
- Bispecific Monoclonal Antibody for Short Bowel Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- crofelemer DR - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Short Bowel Syndrome - Drug Profile
- Product Description
- Mechanism Of Action
- glepaglutide - Drug Profile
- Product Description
- Mechanism Of Action
- GLP-2 - Drug Profile
- Product Description
- Mechanism Of Action
- GLP-2 - Drug Profile
- Product Description
- Mechanism Of Action
- GLP2-ELP - Drug Profile
- Product Description
- Mechanism Of Action
- GXG-8 - Drug Profile
- Product Description
- Mechanism Of Action
- HL-06 - Drug Profile
- Product Description
- Mechanism Of Action
- HM-15912 - Drug Profile
- Product Description
- Mechanism Of Action
- melatonin - Drug Profile
- Product Description
- Mechanism Of Action
- MOD-1501 - Drug Profile
- Product Description
- Mechanism Of Action
- NB-1002 - Drug Profile
- Product Description
- Mechanism Of Action
- QPG-1030 - Drug Profile
- Product Description
- Mechanism Of Action
- SC-403 - Drug Profile
- Product Description
- Mechanism Of Action
- teduglutide - Drug Profile
- Product Description
- Mechanism Of Action
- teduglutide - Drug Profile
- Product Description
- Mechanism Of Action
- vurolenatide - Drug Profile
- Product Description
- Mechanism Of Action
- Short Bowel Syndrome - Dormant Projects
- Short Bowel Syndrome - Discontinued Products
- Short Bowel Syndrome - Product Development Milestones
- Featured News & Press Releases
- Nov 03, 2022: VectivBio announces completion of enrollment for colon-in-continuity (CIC) cohort of STARS pivotal phase 3 study investigating apraglutide in short bowel syndrome with intestinal failure (SBS-IF)
- Oct 13, 2022: VectivBio reports positive interim clinical data from STARS nutrition, a phase 2 study investigating apraglutide in short bowel syndrome with intestinal failure patients (SBS-IF) with Colon-In-Continuity (CIC)
- Oct 03, 2022: Zealand Pharma reports data from Phase III short bowel syndrome trial
- Sep 26, 2022: 9 Meters Biopharma announces positive final results from phase 2 vibrant study and successful end-of-phase 2 meeting with FDA for vurolenatide in short bowel syndrome
- Jul 13, 2022: 9 Meters Biopharma to participate in the William Blair Biotech Focus Conference 2022
- Jun 30, 2022: 9 Meters Biopharma announces debt facility to support phase 3 study of vurolenatide for short bowel syndrome
- Jun 30, 2022: 9 Meters Biopharma announces positive preliminary results from phase 2 study of vurolenatide in short bowel syndrome
- Jun 01, 2022: NICE recommends Revestive (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS)
- May 05, 2022: 9 Meters Biopharma to present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
- Mar 29, 2022: VectivBio presents new clinical data supporting apraglutide for treatment of short bowel syndrome with intestinal failure (SBS-IF) patients who have renal dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference
- Mar 21, 2022: 9 Meters Biopharma to present the clinical milestones for vurolenatide at the Maxim Group 2022 Virtual Growth Conference
- Feb 28, 2022: 9 Meters Biopharma provides clinical update on late-stage pipeline product vurolenatide for short bowel syndrome
- Jan 20, 2022: Zealand Pharma completes enrollment in EASE-SBS 1 phase 3 trial assessing Glepaglutide in patients with short bowel syndrome
- Dec 16, 2021: Zealand Pharma announces enrollment of last patient needed for interim analysis of EASE-SBS 1 phase 3 trial assessing Glepaglutide in patients with short bowel syndrome
- Dec 13, 2021: European Medicines Agency grants Orphan Drug Designation for crofelemer to Napo EU, Jaguar Health’s Italian Subsidiary, for Short Bowel Syndrome
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Short Bowel Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Short Bowel Syndrome - Pipeline by 9 Meters Biopharma Inc, 2022
- Short Bowel Syndrome - Pipeline by Amogen Pharma Pvt Ltd, 2022
- Short Bowel Syndrome - Pipeline by Applied Molecular Transport Inc, 2022
- Short Bowel Syndrome - Pipeline by enGene Inc, 2022
- Short Bowel Syndrome - Pipeline by Entera Bio Ltd, 2022
- Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
- Short Bowel Syndrome - Pipeline by Huons Global Co Ltd, 2022
- Short Bowel Syndrome - Pipeline by Micelle BioPharma Inc, 2022
- Short Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, 2022
- Short Bowel Syndrome - Pipeline by OPKO Health Inc, 2022
- Short Bowel Syndrome - Pipeline by PhaseBio Pharmaceuticals Inc, 2022
- Short Bowel Syndrome - Pipeline by QuiaPEG Pharmaceuticals AB, 2022
- Short Bowel Syndrome - Pipeline by Surrozen Inc, 2022
- Short Bowel Syndrome - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022
- Short Bowel Syndrome - Pipeline by VectivBio Holding AG, 2022
- Short Bowel Syndrome - Pipeline by Worphmed Srl, 2022
- Short Bowel Syndrome - Pipeline by Zealand Pharma AS, 2022
- Short Bowel Syndrome - Dormant Projects, 2022
- Short Bowel Syndrome - Discontinued Products, 2022
- Number of Products under Development for Short Bowel Syndrome, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 9 Meters Biopharma Inc
- Amogen Pharma Pvt Ltd
- Applied Molecular Transport Inc
- enGene Inc
- Entera Bio Ltd
- Hanmi Pharmaceuticals Co Ltd
- Huons Global Co Ltd
- Micelle BioPharma Inc
- Napo Pharmaceuticals Inc
- OPKO Health Inc
- PhaseBio Pharmaceuticals Inc
- QuiaPEG Pharmaceuticals AB
- Surrozen Inc
- Takeda Pharmaceutical Co Ltd
- Tasly Pharmaceutical Group Co Ltd
- VectivBio Holding AG
- Worphmed Srl
- Zealand Pharma AS
